Results 121 to 130 of about 6,564,767 (266)

How Advanced Artificial Intelligence Technologies Shape Drug–Drug and Drug–Target Interaction Modeling

Advanced Science
Drug molecular interactions, including drug–drug interactions (DDIs) and drug–target interactions (DTIs), are critical for drug discovery and clinical safety, increasingly propelled by artificial intelligence (AI) technologies.
Xin Sun, Tong Wang
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Ana Liffey Drug Project: seeds of change 2005 annual report. [PDF]

, 2006
The Ana Liffey Drug Project is a ‘Low Threshold - Harm Reduction’ drug project based in North Inner City ...

core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data

Pharmacogenomics and Personalized Medicine
Nina L Wittwer,1,2 Christoph R Meier,1– 3 Carola A Huber,4 Julie D Moser,1 Henriette E Meyer zu Schwabedissen,5 Samuel S Allemann,6,* Cornelia Schneider1,2,* 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,
Wittwer NL, Meier CR, Huber CA, Moser JD, Meyer zu Schwabedissen HE, Allemann SS, Schneider C   +6 more
doaj  

Ana Liffey Drug Project annual report 1993

, 1994
I note that the Project commenced in 1982 and since that time the range and level of services has been developed significantly. The Project was established at a time when the need for services for people with HIV/AIDS had not become apparent and it ...
Ana Liffey Drug Project
core  

Other title: Controlled drug schedules, violations and penalties

, 2011
"October 2011."Section I. Controlled drug schedules & violations--Section II. Controlled drug violations & penalties--Section III.

core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

MG-ECF: Multi-Granularity Entity-Context Fusion for Drug–Drug Interaction Extraction

Future Internet
Adverse drug–drug interactions (DDIs) are a leading cause of preventable medication-related harm, and their automatic detection from the biomedical literature is critical for pharmacovigilance and clinical decision support.
Hiba Chanaa, Loqman Chakir, El Habib Nfaoui   +2 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source